LWM
SUPN icon

Lenox Wealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Lenox Wealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-8,833
Closed -$404K – 607
2018
Q1 		$404K Sell
8,833
-1,286
-13% -$53.7K 0.13% 101
2017
Q4 		$403K Buy
10,119
+1,531
+18% +$60.5K 0.12% 109
2017
Q3 		$343K Buy
8,588
+581
+7% +$25.1K 0.12% 114
2017
Q2 		$345K Buy
+8,007
New +$285K 0.14% 110

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lenox Wealth Management's SUPN Position: Q2 2018 in Review

Lenox Wealth Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2018, closing a stake of 8,833 shares — an estimated $404K sold.

Lenox Wealth Management first reported a position in SUPN in Q2 2017 and held it in 4 quarters. The position peaked at $404K in Q1 2018. 320 funds tracked by Wall St. Rank hold SUPN as of Q2 2018.

  • Lenox Wealth Management reported no remaining Supernus Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Lenox Wealth Management sold 8,833 Supernus Pharmaceuticals shares in Q2 2018, an estimated $404K.
  • Lenox Wealth Management first reported a position in Supernus Pharmaceuticals in Q2 2017 and held it in 4 quarters.
  • Lenox Wealth Management's Supernus Pharmaceuticals position peaked at $404K in Q1 2018.
  • 320 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2018.

Based on Lenox Wealth Management's 13F filing for Q2 2018, filed 26 Jul 2018.